Japan Plans $189 Billion Bond Issuance as Record Budget Signals Expansionary Fiscal Policy 
Wall Street Ends Higher as S&P 500, Nasdaq Extend Gains Ahead of Holiday Week 
U.S. Dollar Slips as Yen Finds Support on Intervention Signals and Geopolitical Risks Rise 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Gold Price Breaks $4,500 as Safe-Haven Demand and Rate Cut Bets Fuel Rally 
UK Economy Grows 0.1% in Q3 2025 as Outlook Remains Fragile 
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding 
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist 
South Korea Central Bank Warns of Rising Financial Stability Risks Amid Won Volatility 
UBS Warns of Short-Term Risks as Precious Metals Rally to Record Highs 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
